What is HC Wainwright's Estimate for CervoMed Q4 Earnings?

CervoMed Inc. (NASDAQ:CRVO - Free Report) - Investment analysts at HC Wainwright issued their Q4 2024 earnings per share (EPS) estimates for shares of CervoMed in a report issued on Thursday, December 5th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.53) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $42.00 target price on the stock. The consensus estimate for CervoMed's current full-year earnings is ($1.73) per share. HC Wainwright also issued estimates for CervoMed's Q1 2025 earnings at ($0.45) EPS, Q2 2025 earnings at ($0.48) EPS, Q3 2025 earnings at ($0.68) EPS and Q4 2025 earnings at ($0.87) EPS.

CRVO has been the subject of a number of other reports. Roth Mkm initiated coverage on shares of CervoMed in a research report on Friday. They set a "buy" rating and a $45.00 target price for the company. Chardan Capital reissued a "buy" rating and issued a $55.00 price target on shares of CervoMed in a research note on Thursday, November 14th. Finally, D. Boral Capital restated a "buy" rating and issued a $34.00 price objective on shares of CervoMed in a report on Wednesday, November 27th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $48.63.

CervoMed Stock Performance

CRVO stock traded up $2.19 during trading on Friday, hitting $11.91. 579,929 shares of the company's stock traded hands, compared to its average volume of 64,702. The business has a fifty day simple moving average of $12.14 and a two-hundred day simple moving average of $15.14. CervoMed has a 1 year low of $5.85 and a 1 year high of $26.38.

CervoMed (NASDAQ:CRVO - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.55) EPS for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.14). The firm had revenue of $1.94 million for the quarter, compared to the consensus estimate of $1.75 million. CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%.

Institutional Trading of CervoMed

Institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC raised its stake in CervoMed by 5.2% during the 2nd quarter. Renaissance Technologies LLC now owns 32,333 shares of the company's stock worth $554,000 after acquiring an additional 1,600 shares in the last quarter. Fred Alger Management LLC acquired a new stake in shares of CervoMed during the second quarter worth $60,000. Citizens Financial Group Inc. RI boosted its holdings in shares of CervoMed by 13.2% in the third quarter. Citizens Financial Group Inc. RI now owns 30,509 shares of the company's stock valued at $445,000 after acquiring an additional 3,553 shares in the last quarter. FMR LLC acquired a new position in CervoMed during the 3rd quarter worth approximately $56,000. Finally, Rhumbline Advisers acquired a new position in CervoMed during the second quarter worth $96,000. 25.15% of the stock is owned by hedge funds and other institutional investors.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.